SCHEMBL2889568

SCHEMBL2889568

CCOc1cc[c]cc1OCC1CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RIPK1 Q13546 1/20 0.40
ADRB2 P07550 1/20 0.35
HTR1A P08908 1/20 0.35
SLC6A2 P23975 1/20 0.35
HTR2A P28223 1/20 0.35
SLC6A4 P31645 1/20 0.35
ADRA1A P35348 1/20 0.35
HTR2B P41595 1/20 0.35
SLC6A3 Q01959 1/20 0.35
ALDH1A1 P00352 2/20 0.35
KDM4E B2RXH2 1/20 0.35
HRH3 Q9Y5N1 3/20 0.34
HTR2C P28335 2/20 0.33
PDE4B Q07343 1/20 0.33
CNR2 P34972 1/20 0.32
MEN1 O00255 1/20 0.32
USP2 O75604 1/20 0.32
PRNP P04156 1/20 0.32
MAPT P10636 1/20 0.32
HPGD P15428 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6641951 0.88 HRH3 (0.40) ALDH1A1KDM4EHRH3
SCHEMBL127280 0.86 ALDH1A1 (0.39) ADRB2HTR1ASLC6A2HTR2ASLC6A4
SCHEMBL2881056 0.85 PDE4B (0.44) RIPK1PDE4BPARP15PARP10
SCHEMBL2884989 0.85 PDE4B (0.41) RIPK1PDE4B
SCHEMBL20587857 0.81 RIPK1 (0.42) RIPK1HTR2AHTR2BALDH1A1HTR2C
SCHEMBL2887139 0.78 C5AR1 (0.43) RIPK1HTR1ASLC6A2SLC6A4SLC6A3
SCHEMBL17316522 0.78 RIPK1 (0.38) RIPK1HTR2AHTR2BHTR2CCNR2
SCHEMBL2323354 0.78 PDE4B (0.48) PDE4B
SCHEMBL2882597 0.78 SLC6A4 (0.43) RIPK1SLC6A4HTR2CPDE4BPARP15
SCHEMBL2882676 0.78 SLC6A4 (0.40) RIPK1SLC6A4HTR2CPDE4BPARP15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8202880-B2 3-hydroxy-6-phenylphenanthridines as PDE4 inhibitors NYCOMED GMBH (DE) 2012-06-19 US disclosed
US-7776893-B2 Use of PDE4 inhibitors for the treatment of diabetes mellitus NYCOMED GMBH (DE) 2010-08-17 US disclosed
US-7632844-B2 2-hydroxy-6-phenylphenanthridines as PDE-4 inhibitors NYCOMED GMBH (DE) 2009-12-15 US disclosed
US-20090170892-A1 3-Hydroxy-6-phenylphenanthridines as pde4 inhibitors NYCOMED GMBH (DE) 2009-07-02 US disclosed
US-20080319067-A1 2-Hydroxy-6-phenylphenanthridines as PDE-4 inhibitors NYCOMED GMBH 2008-12-25 US disclosed
US-7423046-B2 3-hydroxy-6-phenylphenanthridines as pde-4 inhibitors NYCOMED GMBH (DE) 2008-09-09 US disclosed
US-7329676-B2 2-hydroxy-6-phenylphenanthridines as PDE-4 inhibitors NYCOMED GMBH (DE) 2008-02-12 US disclosed
US-20070259909-A1 Novel Difluoroethoxy-Substituted Hydroxy-6-Phenylphenanthridines and Their Use as Pde4 Inhibitors ALTANA PHARMA AG (DE) 2007-11-08 US disclosed
EP-1536798-B1 3-HYDROXY-6-PHENYLPHENANTHRIDINES AS PDE-4 INHIBITORS ALTANA PHARMA AG (DE) 2007-02-07 EP disclosed
EP-1539164-B1 2-HYDROXY-6-PHENYLPHENANTHRIDINES AS PDE-4 INHIBITORS ALTANA PHARMA AG (DE) 2006-12-20 EP disclosed
US-20050239818-A1 3-hydroxy-6-phenylphenanthridines as pde-4 inhibitors ALANA PHARMA AG (DE) 2005-10-27 US disclosed
WO-2005085203-A1 NOVEL DIFLUOROETHOXY-SUBSTITUTED HYDROXY-6-PHENYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS ALTANA PHARMA AG (DE) 2005-09-15 WO disclosed
EP-1539164-A1 2-HYDROXY-6-PHENYLPHENANTHRIDINES AS PDE-4 INHIBITORS ALTANA Pharma AG (DE) 2005-06-15 EP disclosed
EP-1536798-A1 3-HYDROXY-6-PHENYLPHENANTHRIDINES AS PDE-4 INHIBITORS ALTANA Pharma AG (DE) 2005-06-08 EP disclosed
WO-2005023253-A1 USE OF PDE4 INHIBITORS FOR THE TREATMENT OF DIABETES MELLITUS ALTANA PHARMA AG (DE) 2005-03-17 WO disclosed
WO-2004019945-A1 3-HYDROXY-6-PHENYLPHENANTHRIDINES AS PDE-4 INHIBITORS ALTANA PHARMA AG (DE) 2004-03-11 WO disclosed
WO-2004019944-A1 2-HYDROXY-6-PHENYLPHENANTHRIDINES AS PDE-4 INHIBITORS ALTANA PHARMA AG (DE) 2004-03-11 WO disclosed
US-6476025-B1 Phenylphennanthridines with PDE-IV inhibiting activity ALTANA PHARMA AG (DE) 2002-11-05 US disclosed
EP-1147089-A1 PHENYLPHENANTHRIDINES WITH PDE-IV INHIBITING ACTIVITY Byk Gulden Lomberg Chemische Fabrik GmbH (DE) 2001-10-24 EP disclosed
WO-2000042020-A1 PHENYLPHENANTHRIDINES WITH PDE-IV INHIBITING ACTIVITY BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) 2000-07-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070259909-A1 Novel Difluoroethoxy-Substituted Hydroxy-6-Phenylphenanthridines and Their Use as Pde4 Inhibitors PDE4A, PDE4B, PDE4D RIPK1 4785/4885ADRB2 317/4885HTR1A 1316/4885
US-20080319067-A1 2-Hydroxy-6-phenylphenanthridines as PDE-4 inhibitors PDE4A, PDE4B, PDE3A RIPK1 4361/4885ADRB2 102/4885HTR1A 699/4885
US-20050239818-A1 3-hydroxy-6-phenylphenanthridines as pde-4 inhibitors PDE4A, PDE4B, PDE3A RIPK1 4248/4885ADRB2 229/4885HTR1A 811/4885
US-20090170892-A1 3-Hydroxy-6-phenylphenanthridines as pde4 inhibitors PDE4A, PDE4B, PDE3A RIPK1 4211/4885ADRB2 213/4885HTR1A 838/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.